Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Emerging
Primary summary from verified readiness
- Confidence
- 63% · stale
- Computed at
- 2026-09-22T23:27:14.984527+00:00
- Claimed
- 45
- Reported
- 41
- Verified
- 32
- Gap
- +13
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-09-22
Track; not yet
- Why
- Genuinely promising srRNA dose-sparing and durability signals with growing institutional backing (third Gates Foundation grant, Butantan rabies collaboration), but evidence still stops at Phase 1 immunogenicity in healthy adults with no efficacy endpoint or dated pivotal readout.
- Next
- Watch for a registered/registrational Phase 2-3 (efficacy/non-inferiority vs RabAvert, e.g. via Instituto Butantan) and peer-reviewed effect sizes before treating srRNA as a deployable platform signal
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 7
- Tier 1
- 0
- Tier 2
- 1
- Tier 3
- 6
- Supports
- 4
- Contradicts
- 2
- Context
- 1
- Latest observed
- 2026-06-19
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 2
- 2026-07-19 Reading moved from emerging to emerging.
- 2026-09-22 Reading moved from emerging to emerging.